Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2011 08:30 ET | Source: Mateon Therapeutics

OXiGENE Announces Purchase Agreement for Up to $20 Million With Lincoln Park Capital

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
November 09, 2011 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Third Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
November 03, 2011 16:30 ET | Source: Mateon Therapeutics

OXiGENE Reports Final Data From Phase 2 FALCON Study of ZYBRESTAT in Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
November 02, 2011 07:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Third Quarter 2011 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
September 14, 2011 13:15 ET | Source: Mateon Therapeutics

OXiGENE Presents Data Confirming Survival Benefit of ZYBRESTAT in Patients With Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
September 09, 2011 16:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Changes to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
September 07, 2011 16:30 ET | Source: Mateon Therapeutics

OXiGENE to Present Additional ZYBRESTAT(TM) Survival Data at European Thyroid Association Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
September 01, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Restructuring to Focus Resources on Promising Earlier Stage Clinical Programs

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
August 10, 2011 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
August 03, 2011 17:11 ET | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...